Health Catalyst (HCAT) Q1 2026 earnings review
A Brutal Strategic Reset: Shrinking Top Line, Growing Margins
Health Catalyst is ripping the band-aid off under new CEO Ben Albert. The strategic pivot away from legacy data infrastructure toward high-value clinical applications is causing severe near-term pain: Q1 Revenue dropped 11% YoY, and a massive $95.5M goodwill impairment charge cratered Net Income to -$111M. However, aggressive cost-cutting is working. Adjusted EBITDA surged 46% YoY to $9.1M. Management reinstated full-year guidance, projecting a significantly smaller business ($262.5M midpoint, down 16% from FY25) but signaling confidence in bottom-line stability. The company is effectively shrinking to survive, trading top-line growth for sustainable profitability.
🐂 Bull Case
Despite an $8.7M YoY drop in quarterly revenue, Adjusted EBITDA actually grew by $2.8M. The restructuring efforts, workforce reductions, and shifting resources to India are structurally improving the margin profile.
After suspending full-year guidance in Q4 2025, the new leadership team has quantified the transition pain. Establishing a baseline of $260-$265M in FY26 revenue removes a major overhang and resets market expectations.
🐻 Bear Case
The migration from the legacy DOS platform to Ignite is cannibalizing Technology revenue, while the exit from unprofitable contracts is crushing Professional Services. Top-line contraction is accelerating.
The $95.5M goodwill impairment charge confirms that past acquisitions failed to deliver expected value, raising questions about the return on invested capital over the last few years.
⚖️ Verdict: 🔴
Bearish. While the disciplined cost control and reinstated guidance provide some stability, a company trading at a growth multiple cannot sustain a 16% implied annual revenue contraction without severe multiple compression. The bottom is not yet clearly in sight.
Key Themes
DOS to Ignite Migration: Revenue Cannibalization Accelerating
The transition to the lower-cost Ignite platform is actively shrinking the top line. Technology revenue is Reversing, falling 4% YoY to $49.5M. The press release explicitly flags a 'Potential Churn Analysis' graphic, noting $12.5M in known ARR downsell and another $52M at risk. Management is prioritizing the retention of high-value applications over infrastructure, but this strategy guarantees near-term revenue destruction.
Professional Services Segment Collapsing
Professional Services is severely lagging the company average, making it a critical concern. Revenue plunged 24% YoY (from $27.9M to $21.3M). This Decelerating trend is the result of management actively exiting unprofitable TEMS (Technology-Enabled Managed Services) contracts. While this aids gross margins, it removes a massive chunk of top-line scale.
Massive Goodwill Impairment Highlights Past Failures
The company took a $95.5M impairment charge on goodwill in Q1, following a $110M charge in FY25. This indicates that the fair value of the Technology reporting unit has fallen below its carrying value. Essentially, the premium paid for past 'data platform' acquisitions has been permanently written off. The balance sheet still holds $113M in goodwill, posing a risk for future write-downs.
Aggressive Cost Reductions Shield Margins
Despite the revenue freefall, Adjusted Gross Margin expanded to 51% (up from 49% in 25Q1). Total operating expenses (Adjusted) shrank by $5.4M YoY. Management's execution on Q3 2025 workforce reductions and offshoring R&D/SG&A to India is successfully protecting the bottom line, driving the 46% YoY Adjusted EBITDA growth.
Macro Pressures Continue to Delay Deals
The company continues to cite high interest rates, tariffs, and macroeconomic challenges as risk factors. Previous quarters detailed a $1 trillion cut in Medicaid and delayed Life Sciences deals. These systemic pressures force hospital clients to pocket savings from the Ignite migration rather than reinvesting them in new applications.
Focus on High-Margin AI and IP Applications
To offset the loss of data infrastructure revenue, CEO Ben Albert is centering the new operating model around 'highest-conviction technology opportunities' and proprietary AI-driven technology. By focusing on the stickiest, highest-margin application layers (cost efficiency, clinical improvement), the company aims to rebuild a smaller, but more durable ARR base.
Other KPIs
Reversing. Operating Cash Flow moved sharply opposite to Net Income. While GAAP Net Loss exploded to -$111M, OCF was remarkably positive at $18.5M (up from $0.28M in 25Q1). This discrepancy is primarily driven by the massive $95.5M non-cash goodwill impairment charge, combined with a positive $13.4M change in Deferred Revenue, signaling strong cash collections despite GAAP unprofitability.
Decelerating beautifully. SBC was slashed by 50% YoY from $7.54M in 25Q1. This rapid reduction proves management is honoring their commitment to bring SBC down to mid-to-high single digits as a percentage of revenue (currently at 5.3%), mitigating shareholder dilution during the turnaround.
Guidance
Decelerating. The $69M midpoint implies a 14.5% YoY decline compared to 25Q2 ($80.7M) and a sequential drop from 26Q1 ($70.8M). This reflects the ongoing, intentional exit of TEMS contracts and Ignite migration down-sells.
Stable. The $9.5M midpoint is roughly flat sequentially against 26Q1 ($9.1M) and flat YoY compared to 25Q2 ($9.3M). Management is successfully matching their cost cuts to the pace of revenue declines.
Reversing. After posting $311.1M in FY25, the new $262.5M midpoint implies a severe 15.6% YoY contraction. This quantifies the exact depth of the "strategic reset" trough, abandoning prior long-term targets of $500M to focus purely on core profitable revenue.
Decelerating. The $31.5M midpoint is a 24% decline from FY25's record $41.4M. While the company is profitable on an adjusted basis, the sheer loss of revenue scale makes it mathematically impossible to sustain FY25's peak EBITDA figures.
Key Questions
Goodwill Risk
With $113 million in goodwill remaining on the balance sheet following the massive Q1 impairment, what specific legacy assets are still holding this value, and what triggers could lead to further write-downs?
Application Layer Churn
You highlighted the $35M in data infrastructure ARR under pressure from the Ignite migration. What is the explicit retention rate of the high-margin clinical application layer when a customer downgrades their underlying infrastructure?
Revenue Floor
Given the FY26 guidance of $260-$265M, what quarter do you expect the DOS-to-Ignite migration headwinds and TEMS exits to fully annualize, allowing sequential revenue to establish a firm absolute floor?